Advertisement
Canada markets open in 2 hours 22 minutes
  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CAD/USD

    0.7308
    -0.0012 (-0.17%)
     
  • CRUDE OIL

    82.79
    -0.57 (-0.68%)
     
  • Bitcoin CAD

    90,949.95
    +462.65 (+0.51%)
     
  • CMC Crypto 200

    1,433.05
    +8.95 (+0.63%)
     
  • GOLD FUTURES

    2,330.10
    -12.00 (-0.51%)
     
  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     
  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     
  • NASDAQ futures

    17,699.25
    +92.50 (+0.53%)
     
  • VOLATILITY

    15.85
    +0.16 (+1.02%)
     
  • FTSE

    8,089.33
    +44.52 (+0.55%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6834
    -0.0002 (-0.03%)
     

Favourable Signals For Apyx Medical: Numerous Insiders Acquired Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Apyx Medical Corporation (NASDAQ:APYX), that sends out a positive message to the company's shareholders.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

See our latest analysis for Apyx Medical

Apyx Medical Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when President Charles Goodwin bought US$79k worth of shares at a price of US$1.57 per share. We do like to see buying, but this purchase was made at well below the current price of US$2.40. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

ADVERTISEMENT

Apyx Medical insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

Apyx Medical is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Apyx Medical Insiders Bought Stock Recently

Over the last three months, we've seen significant insider buying at Apyx Medical. Not only was there no selling that we can see, but they collectively bought US$84k worth of shares. This makes one think the business has some good points.

Does Apyx Medical Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 13% of Apyx Medical shares, worth about US$12m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About Apyx Medical Insiders?

It is good to see recent purchasing. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Insiders likely see value in Apyx Medical shares, given these transactions (along with notable insider ownership of the company). So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To that end, you should learn about the 4 warning signs we've spotted with Apyx Medical (including 2 which are potentially serious).

But note: Apyx Medical may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.